Hofmann AF

Language: English
References: 89
Page: 15-27
PDF size: 247.57 Kb.

Text Extraction

Biliary secretion in health and disease is reviewed. The powerful techniques of molecular biology have enabled cloning of the transporters involved in biliary secretion and the enterohepatic circulation of bile acids. This, in turn has permitted elucidation of their function as well as their regulation by nuclear receptors. Bile acid secretion is required for efficient lipid absorption, and bile acids also possess powerful direct and indirect antimicrobial functions in the small intestine. The enterohepatic circulation results from efficient ileal absorption, and is highly regulated at two sites. In the hepatocyte, biosynthesis of bile acids is regulated in negative feedback manner by the nuclear receptor FXR as well as by cytokines and by a peptide (FGF-19) liberated by bile acids from the ileal enterocyte. In the ileal enterocyte, bile acid reclamation is regulated in negative feedback manner by FXR and other nuclear receptors. The bile salt export pump (BSEP) mediates uphill canalicular bile acid secretion. Inborn defects in its function cause intrahepatic cholestasis in infants; inhibition of its function by drugs causes hepatotoxicity. Bile acid therapy is based on correction of bile acid deficiency by supplemental bile acids or displacement in which a noncytotoxic bile acid (ursodeoxycholic acid, ursodiol, UDCA) is administered and dilutes out the endogenous cytotoxic bile acids. Administration of primary bile acids may be lifesaving in inborn defects of bile acid biosynthesis. A synthetic bile acid, norUDCA is absorbed by the biliary ductules after secretion and cures the peribiliary fibrosis occurring in the MDR2^-/- mouse which lacks biliary phospholipid.

REFERENCES

1. Hofmann AF. Overview of bile secretion. In: Schultz SG, ed. Handbook of Physiology. Section on the Gastrointestinal System. American Physiological Society, Bethesda, 1989: 549-566.

2. Hofmann AF. Enterohepatic circulation of bile acids. In: Handbook of Physiology. The Gastrointestinal System. Volume III. Salivary, gastric, pancreatic, and hepatobiliary secretion. Schultz SG, editor. American Physiological Society, Bethesda, 1989: 567-596.

3. Dawson PA, Shneider BL, Hofmann AF. Bile formation and the enterohepatic circulation. In: Barrett KE, Ghishan FK, Merchant JL, Said HM, Wood JD, Johnson LR, eds. Physiology of the Gastrointestinal tract. Elsevier Academic Press, San Diego 2006: 1437-62.

4. Pauli-Magnus C, Stieger B, Meier Y, Kullak-Ublick GA, Meier PJ. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol 2005; 43: 342-57.

5. Chiang JY. Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases. Curr Opin Investig Drugs 2005; 6: 994-1001.

6. Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflugers Arch 2006 (in press).

7. Suchy FJ, Ananthanarayanan M. Bile salt excretory pump: biology and pathobiology. J Pediatr Gastroenterol Nutr 2006; 43 Suppl 1: S10-6.

8. Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv Drug Deliv Rev 2003; 55: 107-24.

9. Keppler D. Uptake and efflux transporters for conjugates in human hepatocytes. Methods Enzymol 2005; 400: 531-42.

10. Suzuki H, Sugiyama Y. Transporters for bile acids and organic anions. Pharm Biotechnol 1999; 12: 387-439.

11. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322-42.

12. Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 2006; 130: 908-25.

13. Eloranta JJ, Meier PJ, Kullak-Ublick GA. Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol 2005; 400: 511-30.

14. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 2006; 25: 6163-9.

15. Meier PJ, Boyer JL. Preparation of basolateral (sinusoidal) and canalicular plasma membrane vesicles for the study of hepatic transport processes. Methods Enzymol 1990; 192: 534-45.

16. Cui Y, Konig J, Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 2001; 60: 934-43.

17. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama Y. Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. Am J Physiol Gastrointest Liver Physiol 2006; 290: G550-6.

18. Abdullah-Sayani A, Bueno-de-Mesquita JM, van de Vijver MJ. Technology Insight: tuning into the genetic orchestra using microarrays—limitations of DNA microarrays in clinical practice. Nat Clin Pract Oncol 2006; 3: 501-16.

19. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics 2006.

20. Tietz P, de Groen PC, Anderson NL, Sims C, Esquer-Blasco R, Meheus L, Raymackers J, et al. Cholangiocyte-specific rat liver proteins identified by establishment of a two-dimensional gel protein database. Electrophoresis 1998; 19: 3207-12.

21. Schmitt S, Prokisch H, Schlunck T, Camp DG, 2nd, Ahting U, Waizenegger T, Scharfe C, et al. Proteome analysis of mitochondrial outer membrane from Neurospora crassa. Proteomics 2006; 6: 72-80.

22. Sai Y, Nies AT, Arias IM. Bile acid secretion and direct targeting of mdr1-green fluorescent protein from Golgi to the canalicular membrane in polarized WIF-B cells. J Cell Sci 1999; 112 (Pt 24): 4535-45.

23. Marzioni M, Glaser SS, Francis H, Phinizy JL, LeSage G, Alpini G. Functional heterogeneity of cholangiocytes. Semin Liver Dis 2002; 22: 227-40.

24. Lucassen J. Hydrolysis and precipitates in carboxylate soap solutions. J Phys Chem 1966; 70: 1824-30.

25. Roda A, Hofmann AF, Mysels KJ. The influence of bile salt structure on self-association in aqueous solutions. J Biol Chem 1983; 258: 6362-70.

26. Hjelm RP, Schteingart CD, Hofmann AF, Thiyagarajan P. The structure of conjugated bile salt-fatty acid monoglyceride mixed colloids: studies by small-angle neutron scattering. J Phys Chem 2000; 523: 299-307.

27. Doege H, Baillie RA, Ortegon AM, Tsang B, Wu Q, Punreddy S, Hirsch D, Watson N, et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 2006; 130: 1245-58.

28. Hofmann AF, Borgstrom B. The intraluminal phase of fat digestion in man: the lipid content of the micellar and oil phases of intestinal content obtained during fat digestion and absorption. J Clin Invest 1964; 43: 247-57.

29. Mansbach CM, 2nd, Cohen RS, Leff PB. Isolation and properties of the mixed lipid micelles present in intestinal content during fat digestion in man. J Clin Invest 1975; 56: 781-91.

30. Dam H, Prange I, Jensen MK, Kallehauge HE, Fenger HJ. Studies on human bile. IV. Influence of ingestion of cholesterol in the form of eggs on the composition of bile in healthy subjects. Z Ernahrungswiss 1971; 10: 178-87.

31. Tangedahl TN, Thistle JL, Hofmann AF, Matseshe JW. Effect of beta-sitosterol alone or in combination with chenic acid on cholesterol saturation of bile and cholesterol absorption in gallstone patients. Gastroenterology 1979; 76: 1341-6.

32. Altmann SW, Davis HR, Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.

33. Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, et al. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther 2006; 28: 849-59.

34. Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem 2003; 278: 48275-82.

35. Lee MH, Lu K, Patel SB. Genetic basis of sitosterolemia. Curr Opin Lipidol 2001; 12: 141-9.

36. Yu L, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J Lipid Res 2004; 45: 301-7.

37. Salen G, Starc T, Sisk CM, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 2006; 130: 1853-7.

38. Hofmann AF, Eckmann L. How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci USA 2006; 103: 4333-4.

39. Lorenzo-Zuniga V, Bartoli R, Planas R, Hofmann AF, Vinado B, Hagey LR, Hernandez JM, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003; 37: 551-7.

40. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006; 103: 3920-5.

41. Lillienau J, Schteingart CD, Hofmann AF. Physicochemical and physiological properties of cholylsarcosine. A potential replacement detergent for bile acid deficiency states in the small intestine. J Clin Invest 1992; 89: 420-31.

42. Schmassmann A, Angellotti MA, Ton-Nu HT, Schteingart CD, Marcus SN, Rossi SS, Hofmann AF. Transport, metabolism, and effect of chronic feeding of cholylsarcosine, a conjugated bile acid resistant to deconjugation and dehydroxylation. Gastroenterology 1990; 98: 163-74.

43. Schmassmann A, Fehr HF, Locher J, Lillienau J, Schteingart CD, Rossi SS, Hofmann AF. Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans. Gastroenterology 1993; 104: 1171-81.

44. Longmire-Cook SJ, Lillienau J, Kim YS, Schteingart CD, Danzinger RG, Esch O, Hofmann AF. Effect of replacement therapy with cholylsarcosine on fat malabsorption associated with severe bile acid malabsorption. Studies in dogs with ileal resection. Dig Dis Sci 1992; 37: 1217-27.

45. Gruy-Kapral C, Little KH, Fordtran JS, Meziere TL, Hagey LR, Hofmann AF. Conjugated bile acid replacement therapy for short-bowel syndrome. Gastroenterology 1999; 116: 15-21.

46. Kapral C, Wewalka F, Praxmarer V, Lenz K, Hofmann AF. Conjugated bile acid replacement therapy in short bowel syndrome patients with a residual colon. Z Gastroenterol 2004;42:583-9.

47. Furst T, Bott C, Stein J, Dressman JB. Enteric-coated cholylsarcosine microgranules for the treatment of short bowel syndrome. J Pharm Pharmacol 2005; 57: 53-60.

48. van Berge Henegouwen GP, Hofmann AF. Nocturnal gallbladder storage and emptying in gallstone patients and healthy subjects. Gastroenterology 1978; 75: 879-85.

49. Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology 2006; 43: 1202-10.

50. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581-91.

51. Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-6.

52. Walters HC, Craddock AL, Fusegawa H, Willingham MC, Dawson PA. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1188-200.

53. Dawson PA, Hubbert M, Haywood J, Craddock AL, Zerangue N, Christian WV, Ballatori N. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 2005; 280: 6960-8.

54. Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, et al. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005; 42: 1270-9.

55. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998; 273: 10046-50.

56. Thompson RJ, Azevedo RA, Galoppo C, Lewindon P, McKiernan P. Cholestatic and metabolic liver diseases: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 Suppl 2: S611-5.

57. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006; 44: 778-87.

58. Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 2005; 314: 876-82.

59. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama Y. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 2006; 34: 1575-81.

60. Hirano H, Kurata A, Onishi Y, Sakurai A, Saito H, Nakagawa H, Nagakura M, et al. High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol Pharm 2006; 3: 252-65.

61. Hayashi H, Takada T, Suzuki H, Onuki R, Hofmann AF, Sugiyama Y. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep. Biochim Biophys Acta 2005; 1738: 54-62.

62. Moschetta A, Xu F, Hagey LR, van Berge-Henegouwen GP, van Erpecum KJ, Brouwers JF, Cohen JC, et al. A phylogenetic survey of biliary lipids in vertebrates. J Lipid Res 2005; 46: 2221-32.

63. Quintao E, Grundy SM, Ahrens EH, Jr. Effects of dietary cholesterol on the regulation of total body cholesterol in man. J Lipid Res 1971; 12: 233-47.

64. Gregus Z, Klaassen CD. Disposition of metals in rats: a comparative study of fecal, urinary, and biliary excretion and tissue distribution of eighteen metals. Toxicol Appl Pharmacol 1986; 85: 24-38.

65. Klaassen CD. Biliary excretion of metals. Drug Metab Rev 1976; 5: 165-96.

66. Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 2006.

67. Crawford AR, Smith AJ, Hatch VC, Oude Elferink RP, Borst P, Crawford JM. Hepatic secretion of phospholipid vesicles in the mouse critically depends on MDR2 or MDR3 P-glycoprotein expression. Visualization by electron microscopy. J Clin Invest 1997; 100: 2562-7.

68. Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, Rudi de Waart D, Hoek, et al. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 2006; 44: 195-204.

69. Shiffman ML, Sugerman HJ, Kellum JM, Moore EW. Changes in gallbladder bile composition following gallstone formation and weight reduction. Gastroenterology 1992; 103: 214-21.

70. Higuchi WI, Liu CL, Adachi Y, Mazer NA, Lee PH. Equilibrium dialysis studies on aqueous taurocholate-lecithin solutions: further validation of the method. Hepatology 1990; 12: 45S-49S; discussion 49S-50S.

71. Duane WC, Wiegand DM. Mechanism by which bile salt disrupts the gastric mucosal barrier in the dog. J Clin Invest 1980; 66: 1044-9.

72. Rosmorduc O, Hermelin B, Boelle PY, Parc R, Taboury J, Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003; 125: 452-9.

73. Wasmuth HE, Glantz A, Keppeler H, Simon E, Bartz C, Rath W, Mattsson LA, et al. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter gene ABCB4. Gut 2006.

74. Venkataramani A, Strong RM, Anderson DS, Gilmore IT, Stokes K, Hofmann AF. Abnormal duodenal bile composition in patients with acalculous chronic cholecystitis. Am J Gastroenterol 1998; 93: 434-41.

75. Hofmann AF, Grundy SM, Lachin JM, Lan SP, Baum RA, Hanson RF, Hersh T, et al. Pretreatment biliary lipid composition in white patients with radiolucent gallstones in the National Cooperative Gallstone Study. Gastroenterology 1982; 83: 738-52.

76. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, et al. 24-norursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in MDR2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-81.

77. Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986; 90: 837-52.

78. Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, Steinbach JH, et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 2005; 42: 1391-8.

79. Yu L, Gupta S, Xu F, Liverman AD, Moschetta A, Mangelsdorf DJ, Repa JJ, et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem 2005; 280: 8742-7.

80. Kosters A, Frijters RJ, Schaap FG, Vink E, Plosch T, Ottenhoff R, Jirsa M, et al. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol 2003; 38: 710-6.

81. Kosters A, Kunne C, Looije N, Patel SB, Oude Elferink RP, Groen AK. The mechanism of ABCG5/ABCG8 in biliary cholesterol secretion in mice. J Lipid Res 2006;47:1959-66.

82. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of cholesterol. J Clin Invest 2002; 110: 671-80.

83. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467-94.

84. Duane WC, Ginsberg RL, Bennion LJ. Effects of fasting on bile acid metabolism and biliary lipid composition in man. J Lipid Res 1976; 17: 211-9.

85. Behar J, Lee KY, Thompson WR, Biancani P. Gallbladder contraction in patients with pigment and cholesterol stones. Gastroenterology 1989; 97: 1479-84.

86. Xiao ZL, Amaral J, Biancani P, Behar J. Impaired cytoprotective function of muscle in human gallbladders with cholesterol stones. Am J Physiol Gastrointest Liver Physiol 2005; 288: G525-32.

87. Lyons MA, Wittenburg H. Cholesterol Gallstone Susceptibility Loci: A Mouse Map, Candidate Gene Evaluation, and Guide to Human LITH Genes. Gastroenterology 2006; 131: 1943-70.

88. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 2005; 41: 1138-43.

89. Mendez-Sanchez N, King-Martinez AC, Ramos MH, Pichardo-Bahena R, Uribe M. The Amerindian’s genes in the Mexican population are associated with development of gallstone disease. Am J Gastroenterol 2004; 99: 2166-70.